Comparative Pharmacology
Head-to-head clinical analysis: PERPHENAZINE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERPHENAZINE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
PERPHENAZINE vs THIOTHIXENE HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Perphenazine is a typical antipsychotic that exerts its effects by blocking postsynaptic dopamine D2 receptors in the brain, particularly in the mesolimbic pathway. It also has antagonistic activity at alpha-adrenergic, histaminergic, and muscarinic receptors.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has affinity for serotonin 5-HT2, histamine H1, and alpha-1 adrenergic receptors, contributing to its therapeutic and adverse effects.
Oral: 4-16 mg 2-4 times daily; maximum 64 mg/day. Intramuscular: 5-10 mg every 6 hours; maximum 30 mg/day. Intravenous: 1-5 mg slow IV every 6 hours; maximum 10 mg/day.
Initial: 2 mg orally three times daily. Maintenance: 15-30 mg orally daily in divided doses. Maximum: 60 mg/day.
None Documented
None Documented
Clinical Note
moderatePerphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone propionate."
Clinical Note
moderatePerphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Perphenazine."
Clinical Note
moderatePerphenazine + Methylphenidate
The terminal elimination half-life of perphenazine is approximately 8–12 hours in adults with normal hepatic function. This supports twice-daily dosing for maintenance therapy. In elderly patients or those with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life ranges from 26 to 36 hours in healthy adults, allowing for once-daily dosing in maintenance therapy. In chronic use, the half-life may be prolonged due to accumulation.
Perphenazine is extensively metabolized in the liver, primarily via CYP2D6, and eliminated predominantly as metabolites in urine (approximately 70%) and feces (about 30%). Less than 1% is excreted unchanged in urine.
Primarily renal and biliary; about 50-60% of a single dose is excreted in the urine as metabolites and unchanged drug within 48 hours, with approximately 30-40% eliminated in feces via biliary secretion. Less than 1% of the parent drug is excreted unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
"The risk or severity of adverse effects can be increased when Perphenazine is combined with Methylphenidate."